Fermenta Biotech has successfully completed its listing on the National Stock Exchange of India (NSE) with effect from August 4, 2026. According to reports from The Hindu BusinessLine, the company announced the successful listing of its equity shares on the exchange, marking a significant milestone in its 75-year journey as a leading Vitamin D3 manufacturer. The listing represents a landmark achievement for the biotechnology company, with the milestone marked by a ceremonial bell-ringing event at NSE's Exchange Plaza in Mumbai's Bandra Kurla Complex. Representatives from the NSE, Fermenta's board, senior management and other stakeholders attended the event.
The company's 2,94,30,987 equity shares of face value ₹5 each have been listed and admitted to dealings on the NSE. As reported by The Hindu BusinessLine, the shares will trade under the symbol FERMENTA and ISIN INE225B01021. The listing provides investors with an additional platform to trade the company's shares alongside its existing BSE listing, with the shares carrying the ISIN INE225B01021. This development provides investors with additional accessibility and liquidity options, complementing the company's long-standing listing on the Bombay Stock Exchange.
According to the company announcement reported by The Hindu BusinessLine, the equity shares will continue to remain listed on the BSE under Scrip Code 506414. This dual listing strategy provides Fermenta Biotech with enhanced market access and liquidity across India's two primary stock exchanges, potentially broadening its investor base and trading opportunities. The company has been listed on the BSE since 1977 and has nearly five decades of experience as a publicly traded enterprise.
Founded in 1951, Fermenta is celebrating its 75th anniversary in 2026 and has expanded from its pharmaceutical and biotechnology roots into a global manufacturing company serving customers in more than 60 countries. The company operates manufacturing facilities in Kullu, Dahej, and Tirupati, along with an R&D center in Thane, serving over 400 customers globally. As reported by The Hindu BusinessLine, the company recently received approval from the Food Safety and Standards Authority of India (FSSAI) for its plant-source Vitamin D3 (Vitadee Green), which can be used in food, health supplements and nutraceutical supplements. Managing Director Prashant Nagre indicated plans to ramp up production over the next three months to capitalize on opportunities in India and overseas markets.
Fermenta Biotech reported total revenue of ₹551 crore for the year ended March 2026, with Vitamin D sales accounting for over 70% of its total revenue. According to The Hindu BusinessLine, the company was previously a subsidiary of DIL (Duphar-Interfran Ltd) and following a reverse merger in 2017-18, Fermenta remained as the listed entity on BSE. Nagre described the NSE listing as a significant milestone in the company's landmark year, emphasizing their commitment to enhancing capabilities across nutrition, food fortification, green chemistry and specialized solutions. The expanded exchange presence is expected to support consistent shareholder engagement and reflect the company's global scale in complex manufacturing and specialized solutions.
